Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

64.22
Delayed Data
As of Sep 28
 -0.35 / -0.54%
Today’s Change
45.45
Today|||52-Week Range
68.12
+8.41%
Year-to-Date
Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo
Sep 28 / Zacks.com - Paid Partner Content
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
Sep 26 / TheStreet.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. AbbVie
Sep 28 / MotleyFool.com - Paid Partner Content
Stock Market News for September 26, 2016
Sep 26 / Zacks.com - Paid Partner Content
Gilead Sciences Stock Downgraded: 3 Things You Need to Know
Sep 28 / MotleyFool.com - Paid Partner Content
AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb
Sep 26 / Zacks.com - Paid Partner Content
Stock Research Reports for Amazon, Boeing & MasterCard
Sep 28 / Zacks.com - Paid Partner Content
Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval
Sep 26 / Zacks.com - Paid Partner Content
FDA Approval of Amjevita Need Not Worry AbbVie Shareholders
Sep 28 / GuruFocus News - Paid Partner Content
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
Sep 24 / MotleyFool.com - Paid Partner Content
Momenta to Regain Rights to Humira Biosimilar from Shire
Sep 28 / Zacks.com - Paid Partner Content
3 Dividend Investing Tips That Could Earn You Thousands
Sep 23 / MotleyFool.com - Paid Partner Content
3 Critical FDA Decisions You Can't Afford to Miss
Sep 27 / MotleyFool.com - Paid Partner Content
3 Top Dividend Stocks for Your Roth IRA
Sep 22 / MotleyFool.com - Paid Partner Content
AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica
Sep 27 / Zacks.com - Paid Partner Content
The Pros and Cons of Buying Gilead Sciences Stock
Sep 22 / MotleyFool.com - Paid Partner Content
Biosimilars in Limelight on FDA Approval of Amgen Drug
Sep 27 / Zacks.com - Paid Partner Content
Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again
Sep 20 / MotleyFool.com - Paid Partner Content
Wall Street Sells Off on Worries Over Clinton-Trump Showdown
Sep 26 / TheStreet.com - Paid Partner Content
Better Buy: Pfizer Inc. vs. AbbVie Inc.
Sep 15 / MotleyFool.com - Paid Partner Content
As Humira Alternative Gets FDA Approval, Is Abbvie in Trouble?
Sep 26 / Zacks.com - Paid Partner Content